SCHEMBL3767586

SCHEMBL3767586

O=C(CN1CCN(c2ccc(-c3ccncc3)nn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
HRH3 Q9Y5N1 5/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TRPV6 Q9H1D0 1/20 0.39
PARP1 P09874 1/20 0.39
MAPT P10636 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM2B Q8NHM5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773927 0.91 ALDH1A1 (0.47) HRH3ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL3767633 0.89 HRH3 (0.46) MAPK1HRH3ALDH1A1SMN1; SMN2KMT2A
SCHEMBL3767453 0.89 HRH3 (0.45) HRH3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3771056 0.89 HRH3 (0.45) HRH3ALDH1A1KDM4EPARP1MAPT
SCHEMBL3767918 0.89 HRH3 (0.47) HRH3SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL3777001 0.89 LMNA (0.44) HRH3ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3767452 0.87 LMNA (0.45) HRH3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3763002 0.87 HRH3 (0.46) MAPK1HRH3ALDH1A1MEN1KMT2A
SCHEMBL3773894 0.87 HRH3 (0.44) HRH3NPC1RAB9AKDM2B
SCHEMBL3771694 0.87 PANK3 (0.48) HRH3NPC1RAB9AKDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 MAPK1 3915/4885HRH3 2/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.